Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Other Non-Current Liabilities (2021 - 2024)

Relay Therapeutics (RLAY) has disclosed Other Non-Current Liabilities for 4 consecutive years, with $11.4 million as the latest value for Q1 2024.

  • Quarterly Other Non-Current Liabilities fell 63.75% to $11.4 million in Q1 2024 from the year-ago period, while the trailing twelve-month figure was $11.4 million through Mar 2024, down 63.75% year-over-year, with the annual reading at $13.2 million for FY2023, 59.21% down from the prior year.
  • Other Non-Current Liabilities for Q1 2024 was $11.4 million at Relay Therapeutics, down from $13.2 million in the prior quarter.
  • The five-year high for Other Non-Current Liabilities was $50.5 million in Q3 2021, with the low at $11.4 million in Q1 2024.
  • Average Other Non-Current Liabilities over 4 years is $35.8 million, with a median of $37.6 million recorded in 2022.
  • The sharpest move saw Other Non-Current Liabilities dropped 5.37% in 2022, then plummeted 63.75% in 2024.
  • Over 4 years, Other Non-Current Liabilities stood at $50.3 million in 2021, then crashed by 35.58% to $32.4 million in 2022, then plummeted by 59.21% to $13.2 million in 2023, then decreased by 13.87% to $11.4 million in 2024.
  • According to Business Quant data, Other Non-Current Liabilities over the past three periods came in at $11.4 million, $13.2 million, and $28.0 million for Q1 2024, Q4 2023, and Q3 2023 respectively.